StrokeNCT07347587
Study on the Accuracy of Determining the Responsible Vessel in Medium Vessel Occlusive Stroke Based on Multi-type CT Evaluation
An observational study of Stroke, run by Xuanwu Hospital, Beijing at 1 site in China.
Trial summary
To evaluate the accuracy of diagnosing the qualifying artery in patients with medium vessel occlusion stroke based on multimodal CT Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke
- How many people
- 622 participants
- Where
- 1 siteChina
- Study dates
- 13 Mar 2025to 13 Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: According to previous literature reports, the prevalence of MeVO stroke accounts for 18% of ischemic stroke. It is estimated that the sensitivity of NCCT + CTA in diagnosing MeVO is 74%. Based on multimodal CT, the sensitivity for diagnosing moderate vascular occlusive stroke can be increased by 15%, reaching 89%. The test level is bilateral 0.05, and the confidence level 1 - β = 0.8. Then, at least 622 research subjects are required. Among them, the number of patients with MeVO, N1 = 622 * 0.18 = 112 cases.
Who may be able to join
- Patients with acute ischemic stroke, without restrictions on gender
- Age ≥ 18 years old
- The time from onset to treatment is within 24 hours (the onset time is defined as the "last-well-time", and the treatment plan is determined according to the patient's wishes and local clinical experience)
- Before the treatment, CT, CTA and CTP examinations were conducted, and the relevant clinical data were complete.
Who cannot join
- Patients with acute intracranial hemorrhage
- Patients whose CTP original images cannot be processed by the CTP post-processing software
- Patients for whom the DICOM format image data of CT, CTP original images and MRI images cannot be obtained, or whose image quality is poor due to various reasons
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, 100053
Shujuan Meng, MD, 01083198082, 1026012717@qq.com
About this study
To evaluate the accuracy of diagnosing the qualifying artery in patients with medium vessel occlusion stroke based on multimodal CT
- Conditions
- Stroke
- Keywords
- medium vessel occlusion, Multimodal CT, CTP
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| NCCT+CTA group | The attending physicians of neurology (with more than 5 years of experience in neuroimaging interpretation and not relevant to this study), without knowing the final radiological report, DSA, MRI results and clinical manifestations, only used baseline non-contrast CT (NCCT) and CTA to determine whether the included cases had moderate vascular occlusion. And record the qualifying artery | |
| NCCT+CTA+CTP group | The attending physicians of neurology (with more than 5 years of experience in neuroimaging interpretation and not relevant to this study), without knowing the final radiological report, DSA, MRI results and clinical manifestations, only used baseline non-contrast CT (NCCT) , CTA and CTP to determine whether the included cases had moderate vascular occlusion. And record the qualifying artery |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in accuracy between the evaluation of MeVO stroke using multimode CT and that using NCCT+CTA
The difference in accuracy between the evaluation of MeVO stroke using multimode CT and that using NCCT+CTA
Measured: at baseline
Secondary outcomes (2)
The time required by the reader to identify the qualifying artery before and after using CTP
The time required by the reader to identify the qualifying artery before and after using CTP
Measured: at baseline
The consistency between the core infarction volume evaluated based on CTP and the final infarction volume obtained from MRI examination within 7 days after the onset
The consistency between the core infarction volume evaluated based on CTP and the final infarction volume obtained from MRI examination within 7 days after the onset
Measured: 7 days after the onset
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start13 Mar 2025
- Primary completion13 Mar 2026 (estimated)
- Study completion13 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- More trials run by Xuanwu Hospital, BeijingThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 622 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xuanwu Hospital, Beijing
- Sponsor type
- University, hospital or other
- Collaborators
- Beijing Hospitals Authority
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07347587
- Sponsor's protocol ID
- XMEC-2025-001
- Status last verified
- Jan 2026
- First submitted
- 9 Jan 2026
- Last updated
- 16 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on the Accuracy of Determining the Responsible Vessel in Medium Vessel Occlusive Stroke Based on Multi-type CT Evaluation
- ClinicalTrials.gov ID
- NCT07347587
- Acronym / sponsor ID
- XMEC-2025-001
- Conditions
- Stroke
- Keywords
- medium vessel occlusion, Multimodal CT, CTP
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 622 participants (estimated)
- Lead sponsor
- Xuanwu Hospital, BeijingUniversity, hospital or other
- Collaborators
- Beijing Hospitals Authority
- Study start
- 13 Mar 2025 (actual)
- Primary completion
- 13 Mar 2026 (estimated)
- Study completion
- 13 Mar 2026 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the accuracy of diagnosing the qualifying artery in patients with medium vessel occlusion stroke based on multimodal CT
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| NCCT+CTA group | – | –The attending physicians of neurology (with more than 5 years of experience in neuroimaging interpretation and not relevant to this study), without knowing the final radiological report, DSA, MRI results and clinical manifestations, only used baseline non-contrast CT (NCCT) and CTA to determine whether the included cases had moderate vascular occlusion. And record the qualifying artery |
| NCCT+CTA+CTP group | – | –The attending physicians of neurology (with more than 5 years of experience in neuroimaging interpretation and not relevant to this study), without knowing the final radiological report, DSA, MRI results and clinical manifestations, only used baseline non-contrast CT (NCCT) , CTA and CTP to determine whether the included cases had moderate vascular occlusion. And record the qualifying artery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- According to previous literature reports, the prevalence of MeVO stroke accounts for 18% of ischemic stroke. It is estimated that the sensitivity of NCCT + CTA in diagnosing MeVO is 74%. Based on multimodal CT, the sensitivity for diagnosing moderate vascular occlusive stroke can be increased by 15%, reaching 89%. The test level is bilateral 0.05, and the confidence level 1 - β = 0.8. Then, at least 622 research subjects are required. Among them, the number of patients with MeVO, N1 = 622 * 0.18 = 112 cases.
Key inclusion criteria (4 listed)
- Patients with acute ischemic stroke, without restrictions on gender
- Age ≥ 18 years old
- The time from onset to treatment is within 24 hours (the onset time is defined as the "last-well-time", and the treatment plan is determined according to the patient's wishes and local clinical experience)
- Before the treatment, CT, CTA and CTP examinations were conducted, and the relevant clinical data were complete.
Key exclusion criteria (3 listed)
- Patients with acute intracranial hemorrhage
- Patients whose CTP original images cannot be processed by the CTP post-processing software
- Patients for whom the DICOM format image data of CT, CTP original images and MRI images cannot be obtained, or whose image quality is poor due to various reasons
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The difference in accuracy between the evaluation of MeVO stroke using multimode CT and that using NCCT+CTA
Time frame: at baseline
The difference in accuracy between the evaluation of MeVO stroke using multimode CT and that using NCCT+CTA
2 secondary outcomes
The time required by the reader to identify the qualifying artery before and after using CTP
Time frame: at baseline
The consistency between the core infarction volume evaluated based on CTP and the final infarction volume obtained from MRI examination within 7 days after the onset
Time frame: 7 days after the onset
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke, run by Xuanwu Hospital, Beijing at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shujuan Meng, MD (01083198082, 1026012717@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in accuracy between the evaluation of MeVO stroke using multimode CT and that using NCCT+CTA (time frame: at baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.